Matthew J. Nyflot

Matthew J. Nyflot

Auto-generated profile, based on publicly available information

Matthew J. Nyflot

Department of Radiation Oncology, University of Washington, Seattle, WA 98195, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2023 in British Journal of Radiology
Verified
Journal Article
Open access
LWLise Wei
Lise Wei
DNDipesh Niraula
Dipesh Niraula
EGEvan D H Gates
Evan D H Gates
JFJie Fu
Jie Fu
YLYi Luo
Yi Luo
SCSunan Cui
Sunan Cui
Multiomics data including imaging radiomics and various types of molecular biomarkers have been increasingly investigated for better diagnosis and therapy in the era of precision oncology. Artificial intelligence (AI) including machine learning (ML) and deep learning (DL) techniques combined with the exponential growth of multiomics data may have great potential to revolutionize cancer subtyping, risk stratification, prognostication, prediction and clinical decision-making. In this article, we first present different categories of multiomics data and their roles in diagnosis and therapy. Second, AI-based data fusion methods and modeling methods as well as different validation schemes are illustrated. Third, the applications and examples of multiomics research in oncology are demonstrated. Finally, the challenges regarding the heterogeneity data set, availability of omics data, and validation of the research are discussed. The transition of multiomics research to real clinics still requires consistent efforts in standardizing omics data collection and analysis, building computational infrastructure for data sharing and storing, developing advanced methods to improve data fusion and interpretability, and ultimately, conducting large-scale prospective clinical trials to fill the gap between study findings and clinical benefits.

5 August 2015 in Journal of Medical Imaging
Verified
Journal Article
Open access
PDF file
MNMatthew J. Nyflot
Matthew J. Nyflot
FYFei Yang
Fei Yang
DBDarrin Byrd
Darrin Byrd
SBStephen R Bowen
Stephen R Bowen
GSGeorge A. Sandison
George A. Sandison
PKPaul E Kinahan
Paul E Kinahan
Image heterogeneity metrics such as textural features are an active area of research for evaluating clinical outcomes with positron emission tomography (PET) imaging and other modalities. However, the effects of stochastic image acquisition noise on these metrics are poorly understood. We performed a simulation study by generating 50 statistically independent PET images of the NEMA IQ phantom with realistic noise and resolution properties. Heterogeneity metrics based on gray-level intensity histograms, co-occurrence matrices, neighborhood difference matrices, and zone size matrices were evaluated within regions of interest surrounding the lesions. The impact of stochastic variability was evaluated with percent difference from the mean of the 50 realizations, coefficient of variation and estimated sample size for clinical trials. Additionally, sensitivity studies were performed to simulate the effects of patient size and image reconstruction method on the quantitative performance of these metrics. Complex trends in variability were revealed as a function of textural feature, lesion size, patient size, and reconstruction parameters. In conclusion, the sensitivity of PET textural features to normal stochastic image variation and imaging parameters can be large and is feature-dependent. Standards are needed to ensure that prospective studies that incorporate textural features are properly designed to measure true effects that may impact clinical outcomes.

13 December 2018 in Medical Physics
Verified
Journal Article
Closed access
PDF file
MNMatthew J. Nyflot
Matthew J. Nyflot
PTPhawis Thammasorn
Phawis Thammasorn
LWLandon S. Wootton
Landon S. Wootton
EFEric C. Ford
Eric C. Ford
WCW. Art Chaovalitwongse
W. Art Chaovalitwongse

1 June 2019 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
JPJan Peeken
Jan Peeken
MBMichael Bernhofer
Michael Bernhofer
MSMatthew B. Spraker
Matthew B. Spraker
DPDaniela Pfeiffer
Daniela Pfeiffer
MDMichal Devecka
Michal Devecka
SCStephanie E. Combs
Stephanie E. Combs

8 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
FNFernando Navarro
Fernando Navarro
HDHendrik Dapper
Hendrik Dapper
RARebecca Asadpour
Rebecca Asadpour
CKCarolin Knebel
Carolin Knebel
MSMatthew B. Spraker
Matthew B. Spraker
JPJan Peeken
Jan Peeken
Background: In patients with soft-tissue sarcomas, tumor grading constitutes a decisive factor to determine the best treatment decision. Tumor grading is obtained by pathological work-up after focal biopsies. Deep learning (DL)-based imaging analysis may pose an alternative way to characterize STS tissue. In this work, we sought to non-invasively differentiate tumor grading into low-grade (G1) and high-grade (G2/G3) STS using DL techniques based on MR-imaging. Methods: Contrast-enhanced T1-weighted fat-saturated (T1FSGd) MRI sequences and fat-saturated T2-weighted (T2FS) sequences were collected from two independent retrospective cohorts (training: 148 patients, testing: 158 patients). Tumor grading was determined following the French Federation of Cancer Centers Sarcoma Group in pre-therapeutic biopsies. DL models were developed using transfer learning based on the DenseNet 161 architecture. Results: The T1FSGd and T2FS-based DL models achieved area under the receiver operator characteristic curve (AUC) values of 0.75 and 0.76 on the test cohort, respectively. T1FSGd achieved the best F1-score of all models (0.90). The T2FS-based DL model was able to significantly risk-stratify for overall survival. Attention maps revealed relevant features within the tumor volume and in border regions. Conclusions: MRI-based DL models are capable of predicting tumor grading with good reproducibility in external validation.

1 September 2015 in Practical Radiation Oncology
Verified
Journal Article
Closed access
MNMatthew J. Nyflot
Matthew J. Nyflot
JZJing Zeng
Jing Zeng
AKAaron S. Kusano
Aaron S. Kusano
ANAvrey Novak
Avrey Novak
TMThomas D. Mullen
Thomas D. Mullen
EFEric C. Ford
Eric C. Ford